C8γ Inhibitors
Chemical inhibitors of C8γ can function through various mechanisms to impede the protein's role in the formation of the membrane attack complex (MAC) as part of the body's innate immune response. Eptifibatide and Tirofiban, for instance, are inhibitors that target platelet aggregation processes. By hindering the glycoprotein IIb/IIIa receptor on platelets, these chemicals can indirectly affect C8γ's availability for incorporation into the MAC, as platelet aggregation can be a source of complement activation. This reduction in platelet-driven complement activation can lower the participation of C8γ in the formation of the MAC, thus functionally inhibiting the protein.
Matrix metalloproteinase (MMP) inhibitors such as Marimastat, Prinomastat, Ilomastat, Andecaliximab, Batimastat, Trocade, Tanomastat, AG3340, and Ro 32-3555 can also modulate the activity of C8γ by impacting the complement system. MMPs are known to influence the complement pathway, and their inhibition can thus decrease the activation of the complement system, leading to a reduced functional presence of C8γ in the MAC. Cilengitide, an integrin antagonist, can indirectly reduce the functionality of C8γ by altering cellular adhesion, which might affect the ability of the complement system to target cells for MAC formation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tirofiban-d6 | 144494-65-5 (unlabeled) | sc-475655 | 1 mg | $450.00 | ||
Tirofiban is a non-peptide antagonist of the platelet glycoprotein IIb/IIIa receptor. It inhibits platelet aggregation, which could indirectly decrease the formation of the MAC where C8γ is essential, by reducing platelet release of factors that promote the complement cascade. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor. Since MMPs can modulate the complement system and potentially release C8γ, inhibition by Marimastat may reduce the local activation of the complement system and subsequent incorporation of C8γ into the MAC. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
Prinomastat is another MMP inhibitor with similar action to Marimastat. By inhibiting MMPs, it may decrease the complement system's activation and the involvement of C8γ in the MAC formation on targeted cells. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
Ilomastat, also an MMP inhibitor, could indirectly reduce the availability of C8γ for the assembly of the MAC by suppressing MMP-mediated modulation of the complement system. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat is a synthetic inhibitor of MMPs, which might reduce the activation of the complement system and consequently decrease the functional activity of C8γ in the MAC. | ||||||
Ro 32-3555 | 190648-49-8 | sc-296277 | 10 mg | $413.00 | 2 | |
Trocade, another MMP inhibitor, could potentially decrease the activation of the complement system. This inhibition could lead to a reduction in C8γ activity within the MAC. | ||||||
PD 166866 | 192705-79-6 | sc-208154 | 5 mg | $300.00 | 1 | |
Tanomastat is an MMP inhibitor that might suppress the complement system's activation and reduce the functional incorporation of C8γ into the MAC. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Cilengitide is an integrin antagonist that inhibits certain cell adhesion processes. By altering cell adhesion, it could indirectly affect the complement system's ability to target cells and consequently the role of C8γ in MAC formation. | ||||||